Crossmark

Targeting acute myeloid leukemia through antibody engineering: innovations in immunotherapy and combination regimens

Crossref DOI link: https://doi.org/10.1007/s10238-025-01764-2

Published Online: 2025-06-24

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Soleimani Samarkhazan, Hamed https://orcid.org/0000-0003-1045-7613
Noormohamadi, Hanieh https://orcid.org/0000-0002-9755-2850
Shafiei, Fatemeh Sadat https://orcid.org/0009-0003-7769-8320
Taghinejad, Zahra https://orcid.org/0000-0001-7373-6092
Maleknia, Mohsen https://orcid.org/0000-0003-4559-6525
Raoufi, Atieh https://orcid.org/0000-0002-1029-751X
Nouri, Sina https://orcid.org/0000-0003-4863-2595
Mohammadi, Mohammad Hossein https://orcid.org/0009-0005-4884-5218
License Information

Text and Data Mining valid from 2025-06-24

Version of Record valid from 2025-06-24
More Information

Article History

Received: 12 May 2025

Accepted: 4 June 2025

First Online: 24 June 2025

Declarations

:

: The authors declare no competing interests.